Table 2 Gene amplification frequencies in invasive carcinoma, DCIS associated with invasive carcinoma, and pure DCIS
From: FGFR1 is amplified during the progression of in situto invasive breast carcinoma
Group | Gene | Pure DCIS | DCIS associated with invasive carcinoma | Invasive carcinoma | Pvaluea | Pvalueb |
|---|---|---|---|---|---|---|
Total | HER2 | 54/175 (30.9) | 48/202 (23.8) | 85/427 (19.9) | 0.004 | 0.122 |
| Â | C-MYC | 17/173 (9.8) | 20/203 (9.9) | 54/427 (12.6) | 0.333 | 0.993 |
| Â | CCND1 | 22/175 (12.6) | 35/201 (17.4) | 61/424 (14.4) | 0.559 | 0.192 |
| Â | FGFR1 | 10/168 (6.0) | 21/196 (10.7) | 52/417 (12.5) | 0.020 | 0.105 |
High grade | HER2 | 46/77 (59.7) | 39/102 (38.2) | 63/183 (34.4) | < 0.001 | 0.004 |
| Â | C-MYC | 12/76 (15.8) | 15/103 (14.6) | 42/183 (23.0) | 0.196 | 0.821 |
| Â | CCND1 | 13/77 (16.9) | 23/102 (22.5) | 30/182 (16.5) | 0.937 | 0.349 |
| Â | FGFR1 | 5/74 (6.8) | 14/97 (14.4) | 28/179 (15.6) | 0.056 | 0.114 |
Low/intermediate grade | HER2 | 8/98 (8.2) | 9/100 (9.0) | 22/230 (9.6) | 0.687 | 0.834 |
| Â | C-MYC | 5/97 (5.2) | 5/100 (5.0) | 11/230 (4.8) | 1.000 | 1.000 |
| Â | CCND1 | 9/98 (9.2) | 12/99 (12.1) | 29/228 (12.7) | 0.362 | 0.504 |
| Â | FGFR1 | 5/94 (5.3) | 7/99 (7.1) | 23/225 (10.2) | 0.158 | 0.614 |